AdvisorShares Investments LLC Invests $1.15 Million in Teva Pharmaceutical Industries Ltd. $TEVA

AdvisorShares Investments LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 36,800 shares of the company’s stock, valued at approximately $1,149,000.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $1,098,060,000. Eurizon Capital SGR S.p.A. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $812,000. Triglav Investments D.O.O. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $156,000. National Pension Service raised its position in shares of Teva Pharmaceutical Industries by 68.8% during the fourth quarter. National Pension Service now owns 3,500,558 shares of the company’s stock worth $109,252,000 after acquiring an additional 1,427,265 shares during the last quarter. Finally, Thoroughbred Financial Services LLC bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $233,000. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on TEVA shares. Bank of America raised their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 2nd. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, Barclays raised their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at $6,131,472.24. The trade was a 47.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. The trade was a 34.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 934,459 shares of company stock valued at $31,122,931. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 2.3%

NYSE TEVA opened at $35.32 on Friday. The business has a 50 day simple moving average of $32.35 and a 200 day simple moving average of $31.33. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The stock has a market capitalization of $40.61 billion, a P/E ratio of 26.56, a P/E/G ratio of 3.34 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion during the quarter. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.